VEGF121b Protein, Human, Recombinant

Catalog No. TMPY-03698

VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9.

VEGF121b Protein, Human, Recombinant

Catalog No. TMPY-03698

VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9.

Pack Size	Price	Availability
50 μg	$296	In Stock
100 μg	$507	7-10 days
200 μg	$865	7-10 days
500 μg	$1,750	7-10 days

Bulk & Custom

Add to Cart

Questions

Select Batch

Resource Download

COA User Guide of Recombinant Proteins

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity	1. Measured by its binding ability in a functional ELISA. Immobilized human VEGF121b at 10μg/mL (100μL/well) can bind human VEGFR2-Fc, the EC50 of human VEGFR2-Fc is 0.06-0.1 μg/mL. 2. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 1-5ng/mL.
Description	VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9.
Species	Human
Expression System	HEK293 Cells
Tag	Tag Free
Accession Number	P15692-9
Synonyms	VPF,VEGF,vascular endothelial growth factor A,MVCD1
Construction	A DNA sequence encoding the human VEGF 121 isoform b (P15692-9) (Met1-Asp147,with last 6 amino acids switch from CDKPRR to SLTRKD ) was expressed. Predicted N terminal: Ala 27
Protein Purity	> 95 % as determined by SDS-PAGE
Molecular Weight	34.10 kDa (predicted); 20 and 16 kDa (reducing condition, due to glycosylation)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy